| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
83,754,000 |
| Market
Cap: |
1.73(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.58 - $23.53 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kura Oncology is a clinical-stage biopharmaceutical company engaged in developing medicines for the treatment of cancer. Co.'s primary product candidate, ziftomenib, is a selective, reversible and oral small molecule inhibitor which blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene. Co.'s second product candidate, tipifarnib, is a selective and orally bioavailable inhibitor of farnesyl transferase. Co. is evaluating tipifarnib in multiple solid tumor and hematologic indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
50,000 |
50,000 |
| Total Buy Value |
$0 |
$0 |
$575,000 |
$575,000 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
108,902 |
108,902 |
125,502 |
| Total Sell Value |
$0 |
$2,177,814 |
$2,177,814 |
$2,411,082 |
| Total People Sold |
0 |
5 |
5 |
6 |
| Total Sell Transactions |
0 |
6 |
6 |
11 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wilson Troy Edward |
President and CEO |
• • – |
2022-10-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,084,300) |
8,394 |
|
- |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2022-08-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(11,985) |
30,525 |
|
- |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2022-08-19 |
4 |
A |
$0.00 |
$0 |
I/I |
41,318 |
41,318 |
|
- |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2022-08-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(59,026) |
1,092,694 |
|
- |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2022-07-14 |
4 |
D |
$0.00 |
$0 |
I/I |
(468,297) |
1,151,720 |
|
- |
|
| Doyle Thomas James |
SVP, Finance & AccountingOffic |
• – – |
2022-02-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
500 |
|
1% |
|
| Doyle Thomas James |
SVP, Finance & AccountingOffic |
• – – |
2022-02-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,610 |
|
1% |
|
| Doyle Thomas James |
SVP, Finance & Accounting |
• – – |
2022-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
8,390 |
15,000 |
|
- |
|
| Grasso Marc |
CFO, CBO |
• – – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
21,900 |
21,900 |
|
- |
|
| Dale Stephen |
Chief Medical Officer |
• – – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
36,900 |
36,900 |
|
- |
|
| Flowers Kirsten |
Chief Commercial Officer |
• – – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
21,900 |
22,511 |
|
- |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
21,900 |
23,035 |
|
- |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2021-03-15 |
4 |
AS |
$29.43 |
$183,951 |
D/D |
(6,250) |
0 |
|
-36% |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2021-03-15 |
4 |
OE |
$19.43 |
$121,438 |
D/D |
6,250 |
6,250 |
|
- |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2020-12-23 |
4 |
D |
$0.00 |
$0 |
I/I |
(175,000) |
1,620,017 |
|
- |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2020-12-15 |
4 |
AS |
$40.60 |
$380,667 |
D/D |
(9,375) |
0 |
|
-32% |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2020-12-15 |
4 |
OE |
$19.43 |
$182,156 |
D/D |
9,375 |
3,125 |
|
- |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2020-12-01 |
4 |
OE |
$6.15 |
$72,908 |
D/D |
11,855 |
39,951 |
|
- |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2020-11-10 |
4 |
AS |
$39.43 |
$246,438 |
D/D |
(6,250) |
0 |
|
-33% |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2020-11-10 |
4 |
OE |
$19.43 |
$121,438 |
D/D |
6,250 |
6,250 |
|
- |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2020-10-08 |
4 |
AS |
$34.00 |
$1,712,580 |
D/D |
(50,370) |
28,096 |
|
2% |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2020-10-08 |
4 |
OE |
$6.15 |
$309,776 |
D/D |
50,370 |
78,466 |
|
- |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2020-10-08 |
4 |
AS |
$34.00 |
$3,629,024 |
I/I |
(106,736) |
0 |
|
2% |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2020-10-07 |
4 |
AS |
$34.00 |
$155,924 |
D/D |
(4,586) |
28,096 |
|
-3% |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2020-10-07 |
4 |
OE |
$6.15 |
$28,204 |
D/D |
4,586 |
32,682 |
|
- |
|
115 Records found
|
|
Page 2 of 5 |
|
|
0.10 (0.48%) 
